**[미래에셋 제약/바이오 김승민]**
**10/12 Daily**

[https://t.me/bioksm](https://t.me/bioksm)


 **글로벌 바이오/제약**
────────────────────
 [FDA, Asahi Kasei의  헤르페스 감염증 치료제 pritelivir 승인](https://news.google.com/rss/articles/CBMizwFBVV95cUxQRVhac2F6NUZzNnhBckpoQ3ZLMGV4bFJzTTIzWlUxSS1pRlMwMGE5SFNvbEJkOXhfUDBrMjlRM0FEMEtZdDVFUkhhMWNUcGRxTnhMeUtrMVk2cnhmLVhLcWcxXzdFWW9uRnNqem0wMURUdUQ5QXBIcmtrWnFJU1ZJNjBqZW0zZm9CXzN1MVdlNWlSdm1yWGEwNWp6MGthZC1CTXItUWNHenVGeTZJY1l6Vm5jVGhwRDkwZ3ZFYnNERTFvUjQzVk9GejhMc2ZKVWc?oc=5)

 [FDA, Teva의 정신분열증 월 1회 주사제 Weltruza 승인](https://news.google.com/rss/articles/CBMitwFBVV95cUxOOXNGN3pjSGNMdGluU1gwMzRlYkdqNW14dVFIRkhBLUFudWxKdk85SUxnaWk4SGVQUDFTbFZlS2FhQTVJeXJvMjFTR25XcmpKVEM1SHlUZlY0czJsMDJGS1N1aFdzTk5wZldTWFkyVVhqdE5KZjdjQkpBd0RScmRiajlDRGtZSmNVUEQwbFNXbGFqaXplNjRjMjhqTnFSOGtWeWsxVE42T3J0ZVkwaFZKX2QwVFI3MEk?oc=5)

 [FDA, 제넨테크 Tecentriq를 3기 결장암 보조 치료 병용 요법으로 승인](https://news.google.com/rss/articles/CBMivAJBVV95cUxQaEd6QlFzVkhaNzQ4YzdxQmxzSnp4N0xFbkI5cGpOM2lIVDFJcFZwb2ZDQlFLdFh3QVhYOU5fdlhJOWZ5NDBUMXZ6UnJJUDk2Wmc5NEw3eVppb2RsX0M3WTFTaUdfcFVLY1NxQmZESms2U21Kd3Zzb0FES2JTcXR4QjROd2p2Zzc3em5zWVFvOWZDVEkwbEFFczVQS0x4eTRWNzgxTVJ1MEVNenZPUGtEc1o0VmJrZzBpNFRZamhMdy1hNE5hREthREc1R19XeGplYnNSVldDaXRtOFBheEdnR0hpQUVkRlA5elU0NDQ2LVlyWG1WZnhHOUdVV0FaZEJmUjdXeTBKcXFkSVRjUnRiWnpCc3dtV3lUUUp2OWVWbWFBX2NfSlhtMk03X2RwT21KenNlWHNhVTFhZEth?oc=5)

 [J&J, ICOTYDE(icotrakinra), 판상 건선 성인·청소년 치료 2년 장기 데이터 발표](https://www.jnj.com/media-center/press-releases/new-johnson-johnson-icotyde-icotrokinra-long-term-data-demonstrate-robust-2-year-results-in-the-treatment-of-adults-and-adolescents-with-plaque-psoriasis)

 [Revolution Medicinese의 Rasonque에 대한 새로운 데이터는 다른 치료법에 대한 가능성을 열어줌](https://endpoints.news/new-data-on-revmeds-rasonque-leave-potential-opening-for-other-treatments/)

 [Biohaven, Ono Pharma와  세포외 IgG Degrader에 대한 전략적 라이선스 계약 체결](https://www.prnewswire.com/news-releases/biohaven-enters-strategic-licensing-agreement-with-ono-pharma-for-extracellular-igg-degraders-in-japan-and-select-asian-regions-lead-candidate-bhv-1300-in-phase-3-for-graves-disease-302901852.html)


 **한국 바이오/제약**
────────────────────
 [K-바이오의약품, 3분기 누적 수출 66억달러…‘역대 최대’ 실적](https://www.thebionews.net/news/articleView.html?idxno=28865)

 [셀트리온'옴리클로' EU 점유율 ‘90%’ 찍고 美 입성… 연말실적 기대감↑](https://www.startuptoday.co.kr/news/articleView.html?idxno=815325)

 [셀트리온 짐펜트라, IV 대비 내시경 반응 38%p 높아…美 처방 근거 확대](https://www.medicopharma.co.kr/news/articleView.html?idxno=69811)

 [삼바 노조 또 파업 예고… 글로벌 수주전 발목 잡나](https://www.segye.com/newsView/20261011511752?OutUrl=google)

 [위고비·마운자로 양강 깨질까…국산 비만약 '에페' 출격](https://www.yonhapnewstv.co.kr/news/AKR20261011072613pi9)

 [HK이노엔 GLP-1 신약, 비만 청소년 임상서 효과 확인](https://news.google.com/rss/articles/CBMibkFVX3lxTFA5cm9YU1lDanNhRkdWUUV6dnZNR0wzLUwtb1hTRG5NSGFRZXk5am5USG1Bdmx5NlF3a05IdzlfTEFCWDZTSTRycGgwVWRwN0psU2pjSkpYbGpyRVhtM21Oc0xSa3NpU3NkWTd2UzNB?oc=5)

────────────────────